{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:16:02Z","timestamp":1774548962858,"version":"3.50.1"},"reference-count":28,"publisher":"MathDoc\/Centre Mersenne","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>This review provides an update on the different therapeutic approaches that have been used to treat SARS-CoV-2 infection, as well as, the resulting paradoxical inflammation disorders.<\/jats:p>","DOI":"10.5802\/crbiol.38","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T05:59:11Z","timestamp":1614146351000},"page":"27-42","source":"Crossref","is-referenced-by-count":4,"title":["COVID-19 and drugs: pathophysiology and therapeutic approaches"],"prefix":"10.5802","volume":"344","author":[{"given":"Patrick","family":"Couvreur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Louvard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3842","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"key2025102316430043542_1","article-title":"Essais cliniques au cours de la pand\u00e9mie Covid-19 : Cibles th\u00e9rapeutiques, exigences m\u00e9thodologiques, imp\u00e9ratifs \u00e9thiques","author":"Avis de l\u2019Acad\u00e9mie Nationale de M\u00e9decine, l\u2019Acad\u00e9mie nationale de Pharmacie et l\u2019Acad\u00e9mie des Sciences","year":"2020","unstructured":"[1] Avis de l\u2019Acad\u00e9mie Nationale de M\u00e9decine, l\u2019Acad\u00e9mie nationale de Pharmacie et l\u2019Acad\u00e9mie des Sciences Essais cliniques au cours de la pand\u00e9mie Covid-19 : Cibles th\u00e9rapeutiques, exigences m\u00e9thodologiques, imp\u00e9ratifs \u00e9thiques, 2020 (https:\/\/www.academie-sciences.fr\/fr\/Rapports-ouvrages-avis-et-recommandations-de-l-Academie\/avis-essais-cliniques-pandemie-covid-19.html)"},{"key":"key2025102316430043542_2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","article-title":"Race to find COVID-19 treatments accelerates","volume":"6485","author":"Kupferschmidt, K.","year":"2020","unstructured":"[2] Kupferschmidt, K.; Cohen, J. Race to find COVID-19 treatments accelerates, Science, Volume 6485 (2020), pp. 1412-1413","journal-title":"Science"},{"issue":"6","key":"key2025102316430043542_3","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.cell.2020.10.039","article-title":"<span class=\"mathjax-formula\" data-tex=\"$\\beta $\"><math xmlns=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mi>\u03b2<\/mi><\/math><\/span>-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway","volume":"183","author":"Ghosh, S.","year":"2020","unstructured":"[3] Ghosh, S.; Dellibovi-Ragheb, T. A.; Kerviel, A.; Pak, E.; Qiu, Q.; Fisher, M.; Takvorian, P. M.; Bleck, C.; Hsu, V. W. et al. \u03b2-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway, Cell, Volume 183 (2020) no. 6, pp. 1520-1535","journal-title":"Cell"},{"key":"key2025102316430043542_4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","author":"Jamillouxa, Y.","year":"2020","unstructured":"[4] Jamillouxa, Y.; Henry, T.; Belotb, A.; Vielb, S.; Fautera, M.; El Jammala, T.; Walzerb, T.; Fran\u00e7oise, B.; S\u00e8vea, P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions, Autoimmun. Rev. (2020), 102567","journal-title":"Autoimmun. Rev."},{"key":"key2025102316430043542_5","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypothesis","volume":"395","author":"Li, H.","year":"2020","unstructured":"[5] Li, H.; Liu, L.; Zhang, D.; Xu, J.; Dai, H.; Tang, N.; Su, X.; Cao, B. SARS-CoV-2 and viral sepsis: observations and hypothesis, Lancet, Volume 395 (2020), pp. 1517-1520","journal-title":"Lancet"},{"key":"key2025102316430043542_6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu, Y.","year":"2020","unstructured":"[6] Wu, Y.; Wang, F.; Shen, C.; Peng, W.; Li, D.; Zhao, C.; Li, Z.; Li, S.; Bi, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, Volume 368 (2020), pp. 1274-1278","journal-title":"Science"},{"key":"key2025102316430043542_7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen, P.","year":"2021","unstructured":"[7] Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N. Engl. J. Med., Volume 384 (2021), pp. 229-237","journal-title":"N. Engl. J. Med."},{"key":"key2025102316430043542_8","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","volume":"19","author":"Rojasa, M.","year":"2020","unstructured":"[8] Rojasa, M.; Rodr\u00edgueza, Y.; Monsalvea, D. M.; Acosta-Ampudiaa, Y.; Camachoc, B.; Gallod, J. E.; Rojas-Villarragae, A.; Ram\u00edrez-Santanaa, C.; D\u00edaz-Coronadof, J. C.; Manriqueg, R.; Mantillaa, R. D.; Shoenfeldh, Y.; Anayaa, J.-M. Convalescent plasma in Covid-19: Possible mechanisms of action, Autoimmun. Rev., Volume 19 (2020), 102554","journal-title":"Autoimmun. Rev."},{"issue":"17","key":"key2025102316430043542_9","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duana, K.","year":"2020","unstructured":"[9] Duana, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl Acad. Sci. USA, Volume 117 (2020) no. 17, pp. 9490-9496","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"12","key":"key2025102316430043542_10","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit, E.","year":"2020","unstructured":"[10] de Wit, E.; Feldmann, F.; Cronina, J.; Jordanc, R.; Okumura, A.; Thomas, T.; Scott, D.; Cihlar, T.; Feldmann, H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc. Natl Acad. Sci. USA, Volume 117 (2020) no. 12, pp. 6771-6776","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key2025102316430043542_11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang, Y.","year":"2020","unstructured":"[11] Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, Volume 395 (2020), pp. 1569-1578","journal-title":"Lancet"},{"key":"key2025102316430043542_12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu, C. M.","year":"2004","unstructured":"[12] Chu, C. M.; Cheng, V. C. C.; Hung, I. F. N.; Wong, M. M. L.; Chan, K. H.; Chan, K. S.; Kao, R. Y. T. et al. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, Volume 59 (2004), pp. 252-256","journal-title":"Thorax"},{"key":"key2025102316430043542_13","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao, B.","year":"2020","unstructured":"[13] Cao, B. et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med., Volume 382 (2020), pp. 1787-1799","journal-title":"N. Engl. J. Med."},{"key":"key2025102316430043542_14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox, R. M.","year":"2020","unstructured":"[14] Cox, R. M.; Wolf, J. D.; Plemper, R. K. Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, Nat. Microbiol., Volume 6 (2020), pp. 11-18","journal-title":"Nat. Microbiol."},{"key":"key2025102316430043542_15","article-title":"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","author":"Ridgeback Biotherapeutics, LP","year":"2021","unstructured":"[15] Ridgeback Biotherapeutics, LP A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19, 2021 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405570)"},{"key":"key2025102316430043542_16","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu, J.","year":"2020","unstructured":"[16] Liu, J.; Cao, R.; Xu, M.; Wang, X.; Zhang, H.; Hu, H.; Li, Y.; Hu, Z.; Zhong, W.; Wang, M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov., Volume 6 (2020), 16","journal-title":"Cell Discov."},{"key":"key2025102316430043542_17","article-title":"Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine\/azithromycin and other regimens in Marseille, France: A retrospective analysis","volume":"36","author":"Lagier, J.-C.","year":"2020","unstructured":"[17] Lagier, J.-C.; Million, M.; Gautret, P.; Colson, P.; Giraud-Gatineau, A.; Gaubert, J.-Y.; Fournier, P.-E.; Stein, A.; Deharo, J.-C. et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine\/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med. Infect. Dis., Volume 36 (2020), 101791","journal-title":"Travel Med. Infect. Dis."},{"key":"key2025102316430043542_18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj, J.","year":"2020","unstructured":"[18] Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients, Science, Volume 369 (2020), pp. 718-724","journal-title":"Science"},{"key":"key2025102316430043542_19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung, I. F.-N.","year":"2020","unstructured":"[19] Hung, I. F.-N. et al. Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet, Volume 395 (2020), pp. 1695-1704","journal-title":"Lancet"},{"key":"key2025102316430043542_20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler, C. G. K.","year":"2020","unstructured":"[20] Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues, Cell, Volume 181 (2020), pp. 1016-1035","journal-title":"Cell"},{"key":"key2025102316430043542_21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jinf.2020.03.039","article-title":"Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1","volume":"81","author":"Fang, X.","year":"2020","unstructured":"[21] Fang, X.; Mei, Q.; Yang, T.; Li, L.; Wang, Y.; Tong, F.; Geng, S.; Pan, A. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1, J. Infect., Volume 81 (2020), pp. 147-178","journal-title":"J. Infect."},{"key":"key2025102316430043542_22","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group","year":"2020","unstructured":"[22] The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA, Volume 324 (2020), pp. 1330-1341","journal-title":"JAMA"},{"key":"key2025102316430043542_23","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu, X.","year":"2020","unstructured":"[23] Xu, X.; Han, M.; Lia, T.; Sunb, W.; Wanga, D.; Fuc, B.; Zhouc, Y.; Zheng, X.; Yange, Y.; Lif, X.; Zhangb, X.; Pane, A.; Weic, H. Effective treatment of severe COVID-19 patients with tocilizumab, Proc. Natl Acad. Sci. USA, Volume 117 (2020), pp. 10970-10975","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key2025102316430043542_24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.09.275","article-title":"The northwell COVID-19 research consortium, comparative survival analysis of immunomodulatory therapy for COVID-19 \u2018Cytokine Storm\u2019","author":"Narain, S.","year":"2020","unstructured":"[24] Narain, S.; Stefanov, D. G.; Chau, A. S.; Weber, A. G.; Marder, G.; Kaplan, B.; Malhotra, P.; Bloom, O.; Liu, A.; Lesser, M. L.; Hajizadeh, N. The northwell COVID-19 research consortium, comparative survival analysis of immunomodulatory therapy for COVID-19 \u2018Cytokine Storm\u2019, Chest (2020)","journal-title":"Chest"},{"key":"key2025102316430043542_25","first-page":"e358","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta, P.","year":"2020","unstructured":"[25] Mehta, P.; Cron, R. Q.; Hartwell, J.; Manson, J.; Tattersall, R. S. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome, Lancet, Volume 2 (2020), p. e358-e367","journal-title":"Lancet"},{"key":"key2025102316430043542_26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijid.2020.09.1486","article-title":"Beneficial effect of corticosteroids in preventing mortality in patients receiving Tocilizumab to treat severe COVID-19 illness","volume":"101","author":"Rubio-Rivas, M.","year":"2020","unstructured":"[26] Rubio-Rivas, M. et al. Beneficial effect of corticosteroids in preventing mortality in patients receiving Tocilizumab to treat severe COVID-19 illness, Int. J. Infect. Dis., Volume 101 (2020), pp. 290-297","journal-title":"Int. J. Infect. Dis."},{"key":"key2025102316430043542_27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1076029620938149","article-title":"COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation","volume":"26","author":"Miesbach, W.","year":"2020","unstructured":"[27] Miesbach, W.; Makris, M. COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation, Clin. Appl. Thromb. Hemost., Volume 26 (2020), pp. 1-7","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"key2025102316430043542_28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming, I.","year":"2004","unstructured":"[28] Hamming, I.; Timens, W.; Bulthuis, M. L. C.; Lely, A. T.; Navis, G.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol., Volume 203 (2004), pp. 631-637","journal-title":"J. Pathol."}],"container-title":["Comptes Rendus. Biologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/item\/10.5802\/crbiol.38.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:59:22Z","timestamp":1761231562000},"score":1,"resource":{"primary":{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/articles\/10.5802\/crbiol.38\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"alternative-id":["10.5802\/crbiol.38"],"URL":"https:\/\/doi.org\/10.5802\/crbiol.38","relation":{},"ISSN":["1631-0691","1768-3238"],"issn-type":[{"value":"1631-0691","type":"print"},{"value":"1768-3238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}